Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.
about
Maintenance therapies for multiple myelomaThe role of maintenance therapy in multiple myelomaReviews of individual patient data (IPD) are useful for geriatrics: an overview of available IPD reviews.Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.Meta-analysis of individual patient data from randomized trials: a review of methods used in practice.Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration.Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study.Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based studyPhase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group.Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyImmunomodulatory drugs in multiple myeloma.Newly diagnosed multiple myeloma.Lenalidomide in the treatment of multiple myeloma: a review.Bortezomib treatment for multiple myeloma.Induction of clinical autoimmune disease by therapeutic interferon-alpha.Stem cell transplantation for multiple myeloma.IMWG consensus on maintenance therapy in multiple myeloma.Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaEvolving treatment strategies for myeloma.Current treatment options for myeloma.Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trialsThe treatment of the elderly multiple myeloma patients.Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell supportTreatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies.Treatment of multiple myeloma: a comprehensive review.Posttransplant maintenance therapy in multiple myeloma: the changing landscape.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Genetic variations in multiple myeloma II: association with effect of treatment.Evolving therapeutic paradigms for multiple myeloma: back to the future.Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents.Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma.Is immunotherapy here to stay in multiple myeloma?Effects of native human leukocyte interferon-alpha and recombinant human interferon-alpha on P3-X63-Ag8.653 mouse myeloma cell growth.Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.
P2860
Q24198800-71F78492-AA30-4D13-90CB-3BC696F942D7Q28071644-852508FB-4806-497C-A9EE-25BD1F78F8C8Q30815345-67F4D4A1-961D-41E8-AE9A-4412736AE73FQ30997153-D93648CF-3491-4E1C-974C-A6932B04C5D5Q31016826-142E2EEE-3153-4C5B-A480-C5E7455B5986Q31058878-9568974C-A319-4CA9-8E93-E82A55D1D76BQ33393257-82C3A9D1-2890-48B6-94C1-A764670166FBQ33710588-C75DD2C5-9048-457F-86F6-430DC79842ACQ33805334-D4207387-D5A3-468D-8499-7C1CC2BE7796Q34095653-841FC942-0D72-4626-AABC-5C96E369B5FCQ34122646-74D9E394-ECCC-4E26-AC1F-F5152D70A473Q34325722-951BFA67-9673-45EE-A666-167C6FC5939AQ34677783-C708D005-1FA9-4FB4-81D8-79DA0D64533CQ34775515-F200BB60-20FB-454C-A5EC-143B4750A76EQ35590997-8D8A51E1-99A7-4951-B418-78B837A5C0DDQ35675529-C13F2E18-41A9-4284-A28D-0D274784C51BQ35692626-734E47B1-5416-44BF-A1BB-786FAAE86DB3Q35876966-06BF3698-BD8F-4F30-84AB-9B6E49BAC03EQ36012111-CCA8F993-6264-4C8B-A23B-B829C5DA0CD3Q36012354-AE14D0A8-3AFE-474C-A96C-30EE4EBADD70Q36163971-44908181-5D43-4817-8172-5E00697B75E6Q36182653-43206BAE-3AE8-4E07-A903-0011B6360279Q36799834-A3994D2C-3D38-4A10-9406-C21965DD9527Q36907828-0FA68364-F5BD-449C-A175-1A1472C316E0Q37334974-981DA12C-E189-4AB2-8B72-44FDA8909EC0Q37373269-8B78B00C-CBAE-4140-B346-B85FF31E2147Q37542173-E44A4EDE-97C5-42B1-9D45-D0410A55921FQ37737800-53F92183-6394-4FFD-81A2-DA1DA032D0FCQ37851944-AD5F55E5-F81C-4C06-B4CA-C9071AFE0B81Q37924890-03F598E6-E29D-4C26-8523-2F6513C2BD3FQ38033590-E39C92C4-7332-45F3-8F34-C224CCE39CC5Q38148272-7E3DF0E3-FF65-4672-B628-C5A45A301AFFQ38191975-85D70E47-D31D-44EB-8C1B-89D15A5FC5ABQ38231358-C425FBF2-14CD-41BA-B855-E2AB6FAC9A83Q38375463-31DC0AFB-25ED-4896-95B8-961C40F4B52EQ38740213-2069E009-39D8-4C13-BCFF-270A29A25302Q38970595-64F5D18B-13F1-4BF9-B2E9-7850C5CF257FQ39084427-6935365D-FC27-4B33-9790-51D0996AED58Q39927018-B337C32A-E2A5-4F7D-BDFD-A733F93E0D42Q40719473-C63AFC5F-1752-401E-916E-0231A1B1297E
P2860
Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Interferon as therapy for mult ...... ized trials and 4012 patients.
@ast
Interferon as therapy for mult ...... ized trials and 4012 patients.
@en
type
label
Interferon as therapy for mult ...... ized trials and 4012 patients.
@ast
Interferon as therapy for mult ...... ized trials and 4012 patients.
@en
prefLabel
Interferon as therapy for mult ...... ized trials and 4012 patients.
@ast
Interferon as therapy for mult ...... ized trials and 4012 patients.
@en
P2860
P1476
Interferon as therapy for mult ...... ized trials and 4012 patients.
@en
P2093
Myeloma Trialists' Collaborative Group
P2860
P304
P356
10.1046/J.1365-2141.2001.02857.X
P407
P577
2001-06-01T00:00:00Z